Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O95294
UPID:
RASL1_HUMAN
Alternative names:
RAS protein activator like 1; Ras GTPase-activating-like protein
Alternative UPACC:
O95294; B7ZKM4; C9JFK5; F8VQX1; Q52M03; Q59H24; Q96CC7
Background:
RasGAP-activating-like protein 1, also known as RAS protein activator like 1 and Ras GTPase-activating-like protein, is a probable inhibitory regulator of the Ras-cyclic AMP pathway. It plays a pivotal role in dendrite formation by melanocytes, highlighting its significance in cellular signaling and morphology.
Therapeutic significance:
Understanding the role of RasGAP-activating-like protein 1 could open doors to potential therapeutic strategies. Its involvement in critical signaling pathways suggests its potential as a target in diseases where these pathways are dysregulated.